Almac Announces Launch of Next Generation Sequencing Service for Personalised Medicine

Almac Announces Launch of Next Generation Sequencing Service for Personalised Medicine

AlmacMichael SloanT: +44 283 833 7575orDe Facto CommunicationsTristan JervisT: +44 207 861 3019M: +44 771 363 8396

today announced that it is launching a service to further expand its range of solutions supporting the development of . The purpose of this service is to support Almac’s BioPharma partners in the development of molecular tests for trial enrichment and companion diagnostic development, specifically focussing on targeted re-sequencing

Almac currently offer solutions using microarray, qPCR and IHC and the addition of the Next Generation Sequencing (NGS) platform fully complements this range of clinically focused diagnostic delivery platforms.

Almac previously launched a service focussing on the analysis of Next Generation Sequencing (NGS) data and based on feedback from the market has decided to develop this service further to include data generation and to allow the delivery of NGS based assays in their lab.

Professor Paul Harkin, President and Managing Director of Almac’s Diagnostics business unit and Professor of Molecular Oncology at Queens University Belfast said:

Almac already perform Next Generation Sequencing for Omixon, a bioinformatics company focused on the development of validated data analysis solutions to scientists working in genomics with special emphasis on clinical and diagnostic applications. Attila Bérces, founder and Chief Executive Officer of Omixon said:

Almac’s Diagnostics business unit is focused on the discovery and development of biomarkers. It utilises its proprietary technology, extensive experience and expertise to offer solutions to biotech and Pharma partners. Almac focus on providing a range of services including exploratory biomarker discovery studies, verification studies for existing markers, assay development and biomarker validation.

The provides a broad range of services from R&D, , , , and (IVRS/IWRS), to . Almac provides services to more than 600 companies, including all the world leaders in the pharmaceutical and biotech sectors. The employs over 3,300 individuals and is headquartered in Craigavon, Northern Ireland. US operations are based in Pennsylvania, North Carolina and California.

For more information about the Almac Group, please visit or e-mail

For media enquiries, please contact Tristan Jervis or Alex Heeley at De Facto Communications on +44 (0) 207 861 3019 or e-mail: .

Suggested Articles

Loretta Itri, M.D. has been helping Immunomedics out with its troubled antibody-drug conjugate. Now, she’s signing on as its chief medical officer.

Light Chain Bioscience, a unit of Swiss biotech Novimmune, has been handed a nice royalty milestone check from partner Takeda.

The fund received money from Chinese organizations inside and outside the biopharma industry, enabling CICC Capital to ease past its financing goal.